Cenk ARAL, Mustafa AKKİRPİK, Filiz ÖZDEMİR SERTOĞLU, Zehra ATABEY, Sıdıka Ayşe ÖZER, Metin ÖZATA, Gökhan ÖZIŞIK, Sinan ÇAĞLAYAN

Association of ACP1 genotypes and clinical parameters in patients with metabolic syndrome

Amaç: Polimorfi k bir enzim olan asit fosfataz lokus 1 (ACP1) insülin direncini etkilemesinden dolayı metabolik sendrom (MS) gelişiminde potansiyel bir öneme sahiptir. Bu çalışmanın amacı, çeşitli metabolik sendrom risk faktörleri ile ACP1 genotip arasında bir ilişkinin olup olmadığını belirlemektir. Yöntem ve gereç: Yetmiş MS hastası ile 168 sağlıklı kontrol grubunda ACP1 genotipi PCR-RFLP yöntemi ile araştırıldı. Bulgular: Çalışmamızda düşük enzim aktivitesine sahip genotip sıklığının, diğer genotiplere kıyaslandığında, hasta grubunda (her iki cinsiyette) kontrol grubundan daha düşük olduğu tespit edilmiştir. Diğer yandan, yüksek enzim aktivitesine sahip genotip sıklığının, kadınlar ve erkekler ayrı ayrı karşılaştırıldığında dahi, hasta grubunda kontrol grubundan daha yüksek olduğu tespit edilmiştir. A* allel sıklığında ise, kontrol ve hasta grupları arasında cinsiyet göz önüne alındığında dahi, bir fark gözlenmemiştir; ancak MS’li kadınların çoğunda vücut kompozisyonu, serum kortizol düzeyi ve kortizolün baskılanabilirliği ile A* alelinin varlığı arasında kuvvetli bir ilişki bulunmuşturSonuç: Bu veriler düşük enzim aktivitesine sahip genotiplerin MS gelişimi için koruyucu bir etkiye sahip olabileceğini göstermektedir. A* allel taşıyıcılığı kadınlarda vücut kompozisyonunu etkilemesine rağmen erkelerde etkili değildir. Ayrıca, A* allelinin varlığı hem serum kortizol düzeyi hem de kortizolün baskılanabilirliği üzerinde, her iki cinsiyet grubunda da, zıt yönde etki gösteriyor olabilir.

Metabolik sendromlu hastalarda klinik parametreler ve ACP1 genotip ilişkisi

Aim: Acid phosphatase locus 1 (ACP1) encodes a polymorphic enzyme and has potential implications for the development of metabolic syndrome (MS) by altering insulin sensitivity. Th e aim of this study was to determine whether a relationship exists between ACP1 genotypes and various metabolic syndrome risk factors. Materials and methods: We employed a PCR-RFLP based genotyping of ACP1 in a cohort of 70 patients with MS and 168 healthy individuals. Results: When compared to controls, genotypes associated with low enzyme activity were observed at signifi cantly lower frequencies in both sexes. Of note, high enzyme activity genotypes were more common in patients with MS when compared with medium and low enzyme activity genotypes. *A allele frequency was not diff erent between patients and controls even considering sex; however, there was a good correlation of the presence of the allele with body composition, serum cortisol levels and suppressibility of cortisol, particularly in women with MS. Conclusion: Our fi ndings suggest that low enzyme activity genotypes seem to be associated with a protective eff ect for the development of MS. Additionally, *A allele carriage aff ects body composition in women but not in men, and the presence of this allele might modulate serum cortisol levels as well as its suppressibility in both sexes, in an inverse manner.

PDF

___

1. Bottini N, Bottini E, Gloria-Bottini F, Mustelin T. Lowmolecular- weight protein tyrosine phosphatase and human disease: in search of biochemical mechanisms. Arch Immunol Th er Exp (Warsz) 2002; 50: 95-104.
2. Spencer N, Hopkinson DA, Harris H. Quantitative diff erences and gene dosage in the human red cell acid phosphatase polymorphism. Nature 1964; 201: 299-300.
3. Dissing J. Immunochemical characterization of human red cell acid phosphatase isozymes. Biochem Genet 1987; 25: 901–917.
4. Boivin P, Galand C. Th e human red cell acid phosphatase is a phosphotyrosine protein phosphatase which dephosphorylates the membrane protein band 3. Biochem Biophys Res Commun 1986; 134: 557-564.
5. Fuchs KR, Shekels LL, Bernlohr DA. Analysis of the ACP1 gene product: classifi cation as an FMN phosphatase. Biochem Biophys Res Commun 1992; 189: 1598-1605.
6. Vogel W, Lammers R, Huang J, Ullrich A. Activation of a phosphotyrosine phosphatase by tyrosine phosphorylation. Science 1993; 259: 1611-1614.
7. Wo YY, McCormack AL, Shabanowitz J, Hunt DF, Davis JP, Mitchell GL et al. Sequencing, cloning, and expression of human red cell-type acid phosphatase, a cytoplasmic phosphotyrosyl protein phosphatase. J Biol Chem 1992; 267:10856-10865.
8. Executive summary of the third report of the Na¬tional Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel UT). Expert Panel on Detection, and Treatment of High Blood Cholesterol in Adults. JAMA 2001; 285: 2486-297.
9. Onat A, Ceyhan K, Başar O, Erer B, Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels—a prospective and cross-sectional evaluation. Atherosclerosis 2002; 165: 285-292.
10. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. National Heart, Lung, and Blood Institute; American Heart Association. Defi nition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientifi c issues related to defi nition. Arterioscler Th romb Vasc Biol 2004; 24: e13-8.
11. Hopkinson DA, Spencer N, Haris H. Red cell acid phosphatase variants: a new human polymorphism. Nature 1963; 199: 969-971.
12. Lazaruk KDA. Molecular genetics of human red cell acid phosphatase. University of California, PhD dissertation (Professor Sensabaugh G.F.), Berkeley, 1995.
13. John SWM, Weitzner G, Rozen R, Scriver CR. A Rapid Procedure for Extracting Genomic DNA from Leukocytes. Nucleic Acid Res 1988; 19: 408.
14. Bottini N, MacMurray J, Peters W, Rostamkhani M, Comings DE. Association of the acid phosphatase (ACP1) gene with triglyceride levels in obese women. Mol Genet Metab 2002; 77:226-229.
15. Iannaccone U, Bergamaschi A, Magrini A, Marino G, Bottini N, Lucarelli P et al. Serum glucose concentration and ACP1 genotype in healthy adult subjects. Metabolism Clinical and Experimental 2005; 54: 891-894.
16. Weigensberg MJ, Toledo-Corral CM, Goran MI. Association between the metabolic syndrome and serum cortisol in overweight Latino youth. J Clin Endocrinol Metab 2008; 93:1372-1378.
17. Travison TG, O’Donnell AB, Araujo AB, Matsumoto AM, McKinlay JB. Cortisol levels and measures of body composition in middle-aged and older men. Clin Endocrinol (Oxf) 2007;67: 71-77.
18. Bjorntorp P. Neuroendocrine perturbations as a cause of insulin resistance. Diabetes Metab Res Rev 1999; 15: 427-441.
19. Bottini N, Meloni GF, Borgiani P, Giorgini A, Buzzetti R, Pozzilli P et al. Genotypes of cytosolic low-molecular-weight protein-tyrosine-phosphatase correlate with age at onset of type 1 diabetes in a sex-specifi c manner. Metabolism 2002; 51: 419-422.
20. Meloni G, Bottini N, Borgiani P, Lucarelli P, Meloni T, Bottini E. Association of the ACP1 genotype with metabolic parameters upon initial diagnosis of type 1 diabetes. Med Sci Monit 2003;9: CR105-8.
21. Lucarini N, Antonacci E, Bottini N, Borgiani P, Faggioni G, Gloria-Bottini F. Phosphotyrosine-protein-phosphatase and diabetic disorders. Further studies on the relationship between low molecular weight acid phosphatase genotype and degree of glycemic control. Dis Markers 1998; 14: 121-125.
22. Desvergne B, Michalik L, Wahli W. Transcriptional regulation of metabolism. Physiol Rev 2006; 86: 465-514.
23. Pandey SK, Yu XX, Watts LM, Michael MD, Sloop KW, Rivard AR et al. Reduction of low molecular weight protein-tyrosine phosphatase expression improves hyperglycemia and insulin sensitivity in obese mice. J Biol Chem 2007; 282: 14291-14299.